Last reviewed · How we verify

Oxycodone 10 mg

Kaplan Medical Center · FDA-approved active Small molecule Quality 2/100

Oxycodone 10 mg, marketed by Kaplan Medical Center, is a well-established pain management medication with a strong presence in the pharmaceutical market. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity and revenue protection. However, the primary risk lies in potential generic competition post-patent expiry, which could erode market share and revenue.

At a glance

Generic nameOxycodone 10 mg
SponsorKaplan Medical Center
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: